Policy & Regulation
Forbius' Phase 1a solid tumour trial of AVID200 completes enrolement
16 October 2019 -

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, has completed enrollment in the Phase 1a solid tumour trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, administered as a monotherapy, it was reported yesterday.

The product is rationally designed to selectively and potently inhibit the main pathogenic TGF-beta isoforms 1 and 3. It spares TGF-beta 2 for optimal safety.

The AVID200-03 trial (NCT03834662) is an open label, multicentre, dose-escalation study concentrated on showcasing the safety of AVID200 monotherapy in patients with advanced or metastatic solid tumour malignancies and no other treatment options. Following a standard 3 + 3 design, a total of 15 patients received AVID200 at 5, 15 and 30mg/kg once every three weeks. Pharmacokinetics and target engagement were also assessed.

Login
Username:

Password: